Most potential drug candidates (90%) fail within the clinical trials, mainly because of lack of efficacy. What if the pharmaceutical industry uses predictive human in vitro models in early drug discovery ?
Grégory MAUBON is Chief Data Officer and digital coordinator at HCS Pharma, a biotech startup focused in high content screening and complex diseases. He manages IT missions and leads digital usages linked to company needs.
He is also a Augmented Reality Evangelist (presenter and lecturer) since 2008, where he created www.augmented-reality.fr and founded in 2010 RA'pro (the augmented reality promotion association). He helped many companies (in several domains) to define precisely their augmented reality needs and supported them in the implementation.
As you may now, in HCS Pharma we strongly believe that the critical point of the human health evolution in next years is the in vitro 3D cell culture, especially for complex diseases like cancer . It’s why we work hard on our exclusive BIOMIMESYS® technology. As experts in HCS and cell imaging, we must master all the process : 3D biological models, 3D cell culture, volumetric pictures acquisition, 3D reconstruction and segmentation of cells and ECM compounds, 3D parameters extraction and, of course, biological interpretations. As explained in our VisuAI R&D project, the 3D reconstruction and segmentation step is not simple.
A publication from R. Lane et al, described the use of Small extracellular vesicles (sEVs) reservoir as a biomarker for Glioblastoma tumor subtyping. In this publication Astrocytes, Glioblastoma cell lines, and Glioblastoma patient-derived stem cells were grown in BIOMIMESYS® hydroscaffold. Read more…
Clinicians and researchers worldwide are actively studying the mechanisms governing the infection of humans by SARS-CoV-2 and its consequences on their health, with the objective is to find effective therapies. We all aknowledge their important Read more…